86 related articles for article (PubMed ID: 18654741)
41. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
42. Effect of probenecid on the biliary excretion of belotecan.
Namkoong EM; Kim IW; Kim DD; Chung SJ; Shim CK
Arch Pharm Res; 2007 Nov; 30(11):1482-8. PubMed ID: 18087819
[TBL] [Abstract][Full Text] [Related]
43. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion.
Merino G; Alvarez AI; Pulido MM; Molina AJ; Schinkel AH; Prieto JG
Drug Metab Dispos; 2006 Apr; 34(4):690-5. PubMed ID: 16434544
[TBL] [Abstract][Full Text] [Related]
44. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
Gupta A; Dai Y; Vethanayagam RR; Hebert MF; Thummel KE; Unadkat JD; Ross DD; Mao Q
Cancer Chemother Pharmacol; 2006 Sep; 58(3):374-83. PubMed ID: 16404634
[TBL] [Abstract][Full Text] [Related]
45. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
46. Simple and sensitive high performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasma.
Vali AM; Shafaghi B; Dadashzadeh S
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Apr; 818(2):205-12. PubMed ID: 15734160
[TBL] [Abstract][Full Text] [Related]
47. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.
Horikawa M; Kato Y; Tyson CA; Sugiyama Y
Drug Metab Pharmacokinet; 2002; 17(1):23-33. PubMed ID: 15618649
[TBL] [Abstract][Full Text] [Related]
48. Transport characteristics of fexofenadine in the Caco-2 cell model.
Petri N; Tannergren C; Rungstad D; Lennernäs H
Pharm Res; 2004 Aug; 21(8):1398-404. PubMed ID: 15359574
[TBL] [Abstract][Full Text] [Related]
49. Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).
Lalloo AK; Luo FR; Guo A; Paranjpe PV; Lee SH; Vyas V; Rubin E; Sinko PJ
BMC Med; 2004 May; 2():16. PubMed ID: 15125776
[TBL] [Abstract][Full Text] [Related]
50. Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs.
Sha X; Fang X
Int J Pharm; 2004 Mar; 272(1-2):161-71. PubMed ID: 15019079
[TBL] [Abstract][Full Text] [Related]
51. Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatography.
Cho JY; Seo HB; Yu KS; Bae KS; Yi SY; Jang IJ; Shin SG
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 784(1):25-31. PubMed ID: 12504179
[TBL] [Abstract][Full Text] [Related]
52. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Kruijtzer CM; Beijnen JH; Rosing H; ten Bokkel Huinink WW; Schot M; Jewell RC; Paul EM; Schellens JH
J Clin Oncol; 2002 Jul; 20(13):2943-50. PubMed ID: 12089223
[TBL] [Abstract][Full Text] [Related]
53. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
[TBL] [Abstract][Full Text] [Related]
54. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers.
Taipalensuu J; Törnblom H; Lindberg G; Einarsson C; Sjöqvist F; Melhus H; Garberg P; Sjöström B; Lundgren B; Artursson P
J Pharmacol Exp Ther; 2001 Oct; 299(1):164-70. PubMed ID: 11561076
[TBL] [Abstract][Full Text] [Related]
55. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative.
Lee JH; Lee JM; Lim KH; Kim JK; Ahn SK; Bang YJ; Hong CI
Ann N Y Acad Sci; 2000; 922():324-5. PubMed ID: 11193913
[No Abstract] [Full Text] [Related]
56. Pharmacokinetics of orally administered camptothecins.
Gupta E; Vyas V; Ahmed F; Sinko P; Cook T; Rubin E
Ann N Y Acad Sci; 2000; 922():195-204. PubMed ID: 11193895
[TBL] [Abstract][Full Text] [Related]
57. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Schellens JH; Maliepaard M; Scheper RJ; Scheffer GL; Jonker JW; Smit JW; Beijnen JH; Schinkel AH
Ann N Y Acad Sci; 2000; 922():188-94. PubMed ID: 11193894
[TBL] [Abstract][Full Text] [Related]
58. The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers.
Li H; Chung SJ; Kim DC; Kim HS; Lee JW; Shim CK
Drug Metab Dispos; 2001 Jan; 29(1):54-9. PubMed ID: 11124230
[TBL] [Abstract][Full Text] [Related]
59. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
[TBL] [Abstract][Full Text] [Related]
60. The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s).
Gupta E; Luo F; Lallo A; Ramanathan S; Vyas V; Rubin E; Sinko P
Anticancer Res; 2000; 20(2A):1013-6. PubMed ID: 10810389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
